Author

Ellen Heimann-Nichols

Observed names: E. Heimann-Nichols, E.K. Heimann-Nichols

Institution: Vanderbilt University Medical Center

Observed institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

OpenAlex ID: A5046760736

Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu

2008 · Vasundhara Varthakavi, Ellen Heimann-Nichols, et al. · Nature Medicine · 41

2591O Efficacy of cabozantinib and nivolumab in cluster 1/2 metastatic clear cell renal cell carcinoma: Results from OPTIC RCC, a phase II trial of a novel RNAseq-based biomarker

2025 · S.M. Haake, K. Beckermann, et al. · Annals of Oncology · 12

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

2023 · Kathryn E. Beckermann, Christine M. Bestvina, et al. · JTO Clinical and Research Reports · 6

Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ oropharyngeal cancer.

2024 · Michael K. Gibson, Richard Roden, et al. · Journal of Clinical Oncology · 3

Phase II Trial Assessing Safety, Efficacy and Immune Correlates of Heterologous Prime-Boost with pBI-11 (IM) and TA-HPV (IM) Plus Pembrolizumab for Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

2024 · M. Gibson, P. Savvides, et al. · International Journal of Radiation Oncology*Biology*Physics · 1

677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer

2023 · Michael K Gibson, Panayiotis Savvides, et al. · Regular and Young Investigator Award Abstracts · 1

Retraction Note: Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu

2010 · Vasundhara Varthakavi, Ellen Heimann-Nichols, et al. · Nature Medicine · 1

Abstract A034: HIF-2-mediated gene expression is highest in metastatic and cluster-exclude clear cell renal cell carcinoma tumors

2026 · Scott M. Haake, Katy Beckermann, et al. · Cancer Research

Reply to “Calcium-modulating cyclophilin ligand does not restrict retrovirus release”

2010 · Vasundhara Varthakavi, Ellen Heimann-Nichols, et al. · Nature Medicine

Works count: 9

Citation count: 65

H-index: 3

I10-index: 2